ChiCTR2300070638 版本V1.2 版本创建时间2023/08/18 21:46:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300070638 

最近更新日期:

Date of Last Refreshed on:

2023-05-28 21:38:54 

注册时间:

Date of Registration:

2023-04-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于“护肾延衰”理念提高围透析期肾衰患者生存质量的中西医结合循证优化研究

Public title:

Study on evidence-based optimization of integrated traditional Chinese and western medicine for improving quality of life of patients with renal failure during peridialysis based on concept of ' protecting kidney and prolonging failure'

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于“护肾延衰”理念提高围透析期肾衰患者生存质量的中西医结合循证优化研究

Scientific title:

Study on evidence-based optimization of integrated traditional Chinese and western medicine for improving quality of life of patients with renal failure during peridialysis based on concept of ' protecting kidney and prolonging failure'

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵静 

研究负责人:

何伟明 

Applicant:

Zhao Jing 

Study leader:

He Weiming 

申请注册联系人电话:

Applicant telephone:

+86 13951850782

研究负责人电话:

Study leader's
telephone:

+86 13851699906

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

13951850782@163.com

研究负责人电子邮件:

Study leader's E-mail:

13851699906@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

汉中路155号江苏省中医院5号楼513

研究负责人通讯地址:

汉中路155号江苏省中医院5号楼513

Applicant address:

155# Hanzhong road Nanjing, Jiangsu

Study leader's address:

155# Hanzhong road Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省中医院

Applicant's institution:

Jiangsu province hospital of TCM

研究负责人所在单位:

江苏省中医院

Affiliation of the Leader:

Jiangsu province hospital of TCM

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022NL-198-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京中医药大学附属医院(江苏省中医院)伦理委员会

Name of the ethic committee:

Ethics Committee of Affiliated Hospital of Nanjing University of Chinese Medicine ( Jiangsu Provincial Hospital of Traditional Chinese Medicine )

伦理委员会批准日期:

Date of approved by ethic committee:

2022-11-04 00:00:00

伦理委员会联系人:

王卯

Contact Name of the ethic committee:

Wang Mao

伦理委员会联系地址:

江苏省南京市汉中路155号

Contact Address of the ethic committee:

155 Hanzhong Road, Nanjing City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 25 86560515

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省中医院

Primary sponsor:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

江苏省南京市秦淮区汉中路155号

Primary sponsor's address:

155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

china

Province:

jiangsu

City:

nanjing

单位(医院):

江苏省中医院

具体地址:

江苏省南京市秦淮区汉中路155号

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Address:

155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province

经费或物资来源:

国家中医药管理局

Source(s) of funding:

National Administration of Traditional Chinese Medicine (NATCM)

研究疾病:

慢性肾脏病  

Target disease:

Chronic kidney disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

评价基于“护肾延衰”理念指导下的中西医结合方案对围透析期患者肾功能进程的影响;明确中西医结合方案对围透析期患者营养状况、生存质量的影响;观察中西医结合方案对透析后患者心脑血管事件发生率的影响;建立围透析期的中西医结合防治体系,在省内推广  

Objectives of Study:

To evaluate the effects of integrated traditional Chinese and western medicine on renal function progression in peridialysis patients under the guidance of the concept of "protecting kidney extension failure". To clarify the influence of integrated traditional Chinese and western medicine on nutritional status and quality of life of peridialysis patients; To observe the effect of integrated Chinese and western medicine on the incidence of cardiovascular and cerebrovascular events in patients after dialysis. Establish a prevention and treatment system of integrated traditional Chinese and western medicine in peridialysis period and popularize it in the province

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合CKD分期诊断标准,且为慢性肾脏病围透析期患者;
(2)年龄18~80周岁;
(3)签署知情同意书。

Inclusion criteria

(1)Patients who meet the diagnostic criteria for CKD staging and are in the peridialysis phase of chronic kidney disease
(2) Aged 18-80;
(3) Signed the informed consent voluntarily.

排除标准:

(1)妊娠或准备妊娠、哺乳期的妇女;
(2)活动期恶性肿瘤、肝硬化失代偿期或造血系统等严重原发性疾病、精神病患者

Exclusion criteria:

(1) women who are pregnant or preparing for pregnancy or breastfeeding;
(2) Active stage malignant tumor, cirrhosis decompensated stage or hematopoietic system and other serious primary diseases, psychiatric patients

研究实施时间:

Study execute time:

From 2022-11-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-19 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

围透析患者组

样本量:

1000

Group:

Group of peridialysis patients

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

nanjing

单位(医院):

江苏省中医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

nanjing

单位(医院):

东南大学附属中大医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Southeast University

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省中西医结合医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Provincial Hospital of Integrated Traditional and Western Medicine

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省第二中医院 

单位级别:

三甲 

Institution
hospital:

Jiangsu Second Hospital of Traditional Chinese Medicine

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京市中医院 

单位级别:

三甲 

Institution
hospital:

Nanjing Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

苏州 

市(区县):

姑苏区 

Country:

China

Province:

Suzhou

City:

单位(医院):

苏州市中医医院 

单位级别:

三甲 

Institution
hospital:

Suzhou Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

南通 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南通市中医院 

单位级别:

三甲 

Institution
hospital:

Nantong Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

苏州 

市(区县):

昆山 

Country:

China

Province:

Suzhou

City:

单位(医院):

昆山市中医医院 

单位级别:

三甲 

Institution
hospital:

Kunshan Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

无锡 

Country:

China

Province:

Jiangsu

City:

Wuxi

单位(医院):

宜兴市人民医院 

单位级别:

三甲 

Institution
hospital:

YiXingPeople’s Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

连云港 

Country:

China

Province:

Jiangsu

City:

Lianyungang

单位(医院):

连云港市中医院 

单位级别:

三甲 

Institution
hospital:

Lianyungang Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

张家港 

Country:

China

Province:

Jiangsu

City:

Zhangjiagang

单位(医院):

张家港市中医医院 

单位级别:

三甲 

Institution
hospital:

Zhangjiagang Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

盐城 

Country:

China

Province:

Jiangsu

City:

Yancheng

单位(医院):

盐城市中医院 

单位级别:

三甲 

Institution
hospital:

Yancheng Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

扬州 

Country:

China

Province:

Jiangsu

City:

Yangzhou

单位(医院):

扬州市中医院 

单位级别:

三甲 

Institution
hospital:

Yangzhou Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

太仓 

Country:

China

Province:

Jiangsu

City:

单位(医院):

太仓市中医医院 

单位级别:

二甲 

Institution
hospital:

Taicang Traditional Chinese Medicine Hospital

Level of the institution:

Grade II Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

常熟 

Country:

China

Province:

Jiangsu

City:

单位(医院):

常熟市中医院 

单位级别:

三乙 

Institution
hospital:

Changshu Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level B hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京市高淳中医院 

单位级别:

二甲 

Institution
hospital:

Nanjing Gaochun Hospital of Traditional Chinese Medicine

Level of the institution:

Grade II Level A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

沭阳中医院 

单位级别:

三乙 

Institution
hospital:

Shuyang Hospital of Traditional Chinese Medicine

Level of the institution:

Grade III Level B hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江阴市中医院 

单位级别:

三乙 

Institution
hospital:

Jiangyin Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Level B hospital

测量指标:

Outcomes:

指标中文名:

血清肌酐

指标类型:

主要指标

Outcome:

Serum creatinine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿素氮

指标类型:

主要指标

Outcome:

urea nitrogen

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿白蛋白肌酐比值

指标类型:

主要指标

Outcome:

UACR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

估算的肾小球滤过率

指标类型:

主要指标

Outcome:

eGFR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量量表

指标类型:

主要指标

Outcome:

Quality of life scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血钾

指标类型:

次要指标

Outcome:

K

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血钙

指标类型:

次要指标

Outcome:

Ca

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血磷

指标类型:

次要指标

Outcome:

P

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甲状旁腺素

指标类型:

次要指标

Outcome:

PTH

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

Sample Name:

1

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

队列研究,不随机

Randomization Procedure (please state who generates the random number sequence and by what method):

no

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-04-19 09:00:38